A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma

Summary: Background: Intravenous vinorelbine plus cisplatin is widely prescribed for the treatment of NSCLC. The objective of this phase II study was to define the efficacy of an oral form of vinorelbine combined with cisplatin for first line treatment of advanced/metastatic NSCLC. Patients and methods: From September 2002 to December 2003, 46 chemotherapy-naive patients received 80mg/m2 of cisplatin on day 1 and oral vinorelbine at 60mg/m2 on days 1 and 8, every 3 weeks. Results: After an independent panel review, the response rate was 37.5 % [95% confidence interval (CI): 22.7–54.2%] in the evaluable population and 32.6% [95% CI: 19.5–48] in the intent-to-treat population. Median progression-free survival was 5.6 months and overall survival was 11.2 months. Grades 3 and 4 neutropenia was observed in 58.7% of patients, with febrile neutropenia and neutropenic infection in 4.3 and 8.7% of patients, respectively. The main non-haematological toxicities were hypotension, fatigue (8.7% for each) and gastrointestinal disorders with rare grades 3 and 4. Conclusions: These results suggest that the combination of cisplatin at 80mg/m2 on day 1 with oral vinorelbine at 60mg/m2 on days 1 and 8, every 3 weeks, is an active regimen, associated with acceptable toxicity. Oral vinorelbine is therefore a good alternative to the i.v. formulation. [Copyright &y& Elsevier]